Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05450692 · ClinicalTrials.gov registry record · Phase 3

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

A Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
594
Enrollment target
20
Study locations

NCT05450692 is a Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 594 participants, above the 280-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (112% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05450692, a Phase 3 study of Advanced or Metastatic Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
594 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Conditions Studied

Advanced or Metastatic Non-Small-Cell Lung Cancer

Interventions

  • DRUG Docetaxel
  • DRUG Durvalumab
  • DRUG Ceralasertib

Study Locations (20)

California

  • Research Site - Los Alamitos
  • Research Site - Los Angeles
  • Research Site - Whittier

Florida

  • Research Site - Jacksonville
  • Research Site - Orlando
  • Research Site - Tampa

Maryland

  • Research Site - Baltimore
  • Research Site - Bethesda
  • Research Site - Rockville

Georgia

  • Research Site - Athens
  • Research Site - Atlanta

North Carolina

  • Research Site - Charlotte
  • Research Site - Winston-Salem

Alabama

  • Research Site - Mobile

Arizona

  • Research Site - Chandler

Indiana

  • Research Site - Fort Wayne

Trial Details

FieldValue
Enrollment Target 594 participants
Start Date 2022-09-15
Est. Completion 2026-10-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05450692

The ClinicalTrials.gov registry entry for NCT05450692 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 280-participant average among 3 other Advanced or Metastatic Non-Small-Cell Lung Cancer trials with a reported enrollment target (112% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT05450692 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT05450692 about?

NCT05450692 is a clinical study titled "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy". This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

What is the current status of trial NCT05450692?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2022-09-15. Estimated completion is 2026-10-30.

What conditions does trial NCT05450692 study?

This clinical trial studies the following conditions: Advanced or Metastatic Non-Small-Cell Lung Cancer.

What interventions are being tested in trial NCT05450692?

The interventions under investigation include: Docetaxel (DRUG), Durvalumab (DRUG), Ceralasertib (DRUG).

Who is sponsoring clinical trial NCT05450692?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05450692 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Non-Small-Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Non-Small-Cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.